Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Clin Cancer Res. 2018 Oct 29;25(7):2116–2126. doi: 10.1158/1078-0432.CCR-18-2293

Figure 3.

Figure 3.

Genomic determinants of response to immune checkpoint blockade in patients with advanced HCC. A, Waterfall plot for 27 evaluable patients treated with immune checkpoint blockade showing best change in target lesions for each patient, annotated with response and most frequent genomic alterations. B, Kaplan-Meier PFS on immune oncology agent (IO) for patients with WNT- activated tumors versus non-WNT- activated tumors, demonstrating shorter PFS in WNT-activated HCCs. C, Kaplan-Meier PFS on sorafenib therapy for patients with WNT-activated tumors versus non- WNT-activated tumors, demonstrating equivalent PFS in WNT-activated HCCs.